{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:29:59Z","timestamp":1793996999455,"version":"4.8.0"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Type I interferons (IFNs), particularly IFN-\u03b1, occupy a central paradox in HIV-1 infection: they provide an essential early antiviral barrier that limits initial dissemination, yet their sustained activation contributes to chronic immune activation, CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cell dysfunction, and incomplete viral control. This duality\u2014protective in acute infection but pathogenic during chronic disease\u2014remains a major unresolved challenge for interferon-based therapeutic strategies in HIV-1. Recent advances in ISG functional profiling, IFN-\u03b1 subtype\u2013specific antiviral potency, and the development of targeted innate-pathway modulators (e.g., STING-selective agonists, ncRNA regulators, TLR7 activators) have renewed interest in reevaluating interferon-centered approaches. These developments make it timely to reassess whether IFN-\u03b1 can be safely and effectively integrated into modern HIV-1 therapeutic concepts, particularly in early-infection windows or in rationally designed combination regimens. In this review, we synthesize current knowledge of interferon-mediated restriction mechanisms, the hierarchy of key antiviral ISGs (e.g., APOBEC3G, MX2, BST2), and HIV-1 evasion of the JAK\u2013STAT and cGAS\u2013STING pathways. We further analyze how dose, timing, and IFN-\u03b1 subtype contribute to divergent antiviral versus inflammatory outcomes across different stages of infection. Emerging precision strategies that modulate interferon signaling without triggering systemic inflammation offer promising translational directions. Balancing antiviral efficacy with immune homeostasis will be essential for developing next-generation interferon-based interventions aimed at durable control or functional cure of HIV-1 infection.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1736658","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:43:05Z","timestamp":1766040185000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Interferons in HIV-1 infection: mechanisms, antiviral potentials, and therapeutic challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Luying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"Schoggins","year":"2011","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12653","article-title":"MX2 is an interferon-induced inhibitor of HIV-1 infection","volume":"502","author":"Kane","year":"2013","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature12542","article-title":"Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection","volume":"502","author":"Goujon","year":"2013","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.07.004","article-title":"From rare disorders of immunity to common determinants of infection: Following the mechanistic thread","volume":"185","author":"Casanova","year":"2022","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13075-019-1878-y","article-title":"High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus","volume":"21","author":"Oke","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202753","article-title":"The type I IFN signature as a biomarker of preclinical rheumatoid arthritis","volume":"72","author":"Lubbers","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B9","first-page":"31","article-title":"Increased expression of interferon-lambda in minor salivary glands of patients with primary Sjogren\u2019s syndrome and its synergic effect with interferon-alpha on salivary gland epithelial cells","author":"Ha","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.cell.2020.10.046","article-title":"Human T-bet governs innate and innate-like adaptive IFN-gamma immunity against mycobacteria","volume":"183","author":"Yang","year":"2020","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1056\/NEJM198607033150102","article-title":"Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy","volume":"315","author":"Nathan","year":"1986","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00272-10","article-title":"Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections","volume":"84","author":"Mordstein","year":"2010","journal-title":"J Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PloS Pathog"},{"key":"B14","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ni.3180","article-title":"Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection","volume":"16","author":"Hernandez","year":"2015","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140995","article-title":"IFN-lambda resolves inflammation via suppression of neutrophil infiltration and IL-1beta production","volume":"212","author":"Blazek","year":"2015","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201100142","article-title":"IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease","volume":"3","author":"Koltsida","year":"2011","journal-title":"EMBO Mol Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aan5357","article-title":"Type III interferon is a critical regulator of innate antifungal immunity","volume":"2","author":"Espinosa","year":"2017","journal-title":"Sci Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040874","article-title":"CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract","volume":"200","author":"Brenchley","year":"2004","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B20","volume-title":"Hepatitis C: Diagnosis, Management, and Prevention \u2013 Global Guidelines","year":"2017"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000495897","article-title":"Type I interferons: distinct biological activities and current applications for viral infection","volume":"51","author":"Li","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02427-15","article-title":"Antiviral activities of different interferon types and subtypes against hepatitis E virus replication","volume":"60","author":"Todt","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.chom.2016.08.005","article-title":"Identification of interferon-stimulated genes with antiretroviral activity","volume":"20","author":"Kane","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit628","article-title":"Hepatitis C therapy with interferon-alpha and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1\/hepatitis C virus-coinfected patients","volume":"209","author":"Sun","year":"2014","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107270-00014","article-title":"Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study","volume":"15","author":"Emilie","year":"2001","journal-title":"AIDS"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1086\/652420","article-title":"Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial","volume":"201","author":"Asmuth","year":"2010","journal-title":"J Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.8613","article-title":"Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer","volume":"25","author":"Gollob","year":"2007","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-136660","article-title":"Long-term treatment of hairy cell leukemia patients with interferon: clinical and molecular aspects","volume":"136","author":"Assanto","year":"2020","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"106737","DOI":"10.1016\/j.leukres.2021.106737","article-title":"A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML","volume":"111","author":"Webster","year":"2021","journal-title":"Leuk Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.12.018","article-title":"Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)","volume":"64","author":"Chan","year":"2016","journal-title":"J Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2008.09.016","article-title":"Transcription factor E2\u20132 is an essential and specific regulator of plasmacytoid dendritic cell development","volume":"135","author":"Cisse","year":"2008","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0909635","article-title":"Plasmacytoid dendritic cells in HIV infection: striking a delicate balance","volume":"87","author":"Fitzgerald-Bocarsly","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature00939","article-title":"Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein","volume":"418","author":"Sheehy","year":"2002","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature10117","article-title":"SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx","volume":"474","author":"Laguette","year":"2011","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01844-08","article-title":"Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections","volume":"83","author":"Stacey","year":"2009","journal-title":"J Virol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.08.006","article-title":"Resistance of transmitted founder HIV-1 to IFITM-mediated restriction","volume":"20","author":"Foster","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature13554","article-title":"Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression","volume":"511","author":"Sandler","year":"2014","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89488","article-title":"Targeting type I interferon-mediated activation restores immune function in chronic HIV infection","volume":"127","author":"Zhen","year":"2017","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"crossref","first-page":"e56527","DOI":"10.1371\/journal.pone.0056527","article-title":"Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers","volume":"8","author":"Hardy","year":"2013","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nm0295-129","article-title":"Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes","volume":"1","author":"Finkel","year":"1995","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.cell.2010.11.001","article-title":"Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue","volume":"143","author":"Doitsh","year":"2010","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600363103","article-title":"Differential expression of IFN-alpha and TRAIL\/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients","volume":"103","author":"Herbeuval","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nri2674","article-title":"The immune response during acute HIV-1 infection: clues for vaccine development","volume":"10","author":"McMichael","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e3283495996","article-title":"Innate immunity in acute HIV-1 infection","volume":"6","author":"Borrow","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0799-2","article-title":"Integrated single-cell analysis of multicellular immune dynamics during hyperacute HIV-1 infection","volume":"26","author":"Kazer","year":"2020","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/v17030366","article-title":"Acute HIV-1 infection: paradigm and singularity","volume":"17","author":"Cheret","year":"2025","journal-title":"Viruses"},{"key":"B47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.immuni.2015.08.012","article-title":"Magnitude and kinetics of CD8+ T cell activation during hyperacute HIV infection impact viral set point","volume":"43","author":"Ndhlovu","year":"2015","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092378","article-title":"The landscape of IFN\/ISG signaling in HIV-1-infected macrophages and its possible role in the HIV-1 latency","volume":"10","author":"Rojas","year":"2021","journal-title":"Cells"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273763","article-title":"Evidence of dysregulation of dendritic cells in primary HIV infection","volume":"116","author":"Sabado","year":"2010","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402066","article-title":"Positive feedback regulation of type I IFN production by the IFN-inducible DNA sensor cGAS","volume":"194","author":"Ma","year":"2015","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.1240933","article-title":"Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses","volume":"341","author":"Gao","year":"2013","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311669110","article-title":"IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication","volume":"110","author":"Jakobsen","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00854-10","article-title":"Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells","volume":"84","author":"Goujon","year":"2010","journal-title":"J Virol"},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1111573109","article-title":"Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo","volume":"109","author":"Pillai","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e30306","DOI":"10.1371\/journal.pone.0030306","article-title":"Interferon-alpha administration enhances CD8+ T cell activation in HIV infection","volume":"7","author":"Manion","year":"2012","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01541-18","article-title":"Interferon alpha enhances NK cell function and the suppressive capacity of HIV-specific CD8(+) T cells","volume":"93","author":"Kwaa","year":"2019","journal-title":"J Virol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01167-5","article-title":"The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond","volume":"21","author":"Ngo","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01823","article-title":"Type I interferon responses by HIV-1 infection: association with disease progression and control","volume":"8","author":"Soper","year":"2017","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00206-06","article-title":"Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells","volume":"80","author":"Chen","year":"2006","journal-title":"J Virol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky191","article-title":"IFIT3 and IFIT2\/3 promote IFIT1-mediated translation inhibition by enhancing binding to non-self RNA","volume":"46","author":"Fleith","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nature10623","article-title":"HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase","volume":"480","author":"Goldstone","year":"2011","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat0843","article-title":"CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans","volume":"4","author":"El-Diwany","year":"2018","journal-title":"Sci Adv"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1007408","DOI":"10.1371\/journal.ppat.1007408","article-title":"Multiple components of the nuclear pore complex interact with the amino-terminus of MX2 to facilitate HIV-1 restriction","volume":"14","author":"Dicks","year":"2018","journal-title":"PloS Pathog"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.1038\/s41564-019-0402-0","article-title":"Immunoproteasome activation enables human TRIM5alpha restriction of HIV-1","volume":"4","author":"Jimenez-Guardeno","year":"2019","journal-title":"Nat Microbiol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02478-09","article-title":"The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process","volume":"84","author":"Pincetic","year":"2010","journal-title":"J Virol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nature06553","article-title":"Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu","volume":"451","author":"Neil","year":"2008","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"112556","DOI":"10.1016\/j.celrep.2023.112556","article-title":"Several cell-intrinsic effectors drive type I interferon-mediated restriction of HIV-1 in primary CD4(+) T cells","volume":"42","author":"Itell","year":"2023","journal-title":"Cell Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.198.Supp.158.12","article-title":"Identification of CMPK2 as an interferon stimulated gene that restricts HIV infection","volume":"198","author":"Soliman","year":"2017","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/nature12769","article-title":"HIV-1 evades innate immune recognition through specific cofactor recruitment","volume":"503","author":"Rasaiyaah","year":"2013","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13072-019-0253-1","article-title":"The long non-coding RNA Kcnq1ot1 controls maternal p57 expression in muscle cells by promoting H3K27me3 accumulation to an intragenic MyoD-binding region","volume":"12","author":"Andresini","year":"2019","journal-title":"Epigenet Chromatin"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-021-02325-2","article-title":"Risk of carcinogenesis in the biliary epithelium of children with congenital biliary dilatation through epigenetic and genetic regulation","volume":"52","author":"Mori","year":"2022","journal-title":"Surg Today"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4161\/epi.4.5.9242","article-title":"Epigenetics of imprinted long non-coding RNAs","volume":"4","author":"Mohammad","year":"2009","journal-title":"Epigenetics"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2017.06.003","article-title":"Regulatory mechanisms of long noncoding RNAs on gene expression in cancers","author":"Sun","year":"2017","journal-title":"Cancer Genet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1742-4690-10-128","article-title":"Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice","volume":"10","author":"Dave","year":"2013","journal-title":"Retrovirology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02372-20","article-title":"SERINC5 can enhance proinflammatory cytokine production by primary human myeloid cells in response to challenge with HIV-1 particles","volume":"95","author":"Pierini","year":"2021","journal-title":"J Virol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00836-11","article-title":"Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2","volume":"85","author":"Friedman","year":"2011","journal-title":"J Virol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13148-018-0441-z","article-title":"Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins","volume":"10","author":"Khan","year":"2018","journal-title":"Clin Epigenetics"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e1000495","DOI":"10.1371\/journal.ppat.1000495","article-title":"Epigenetic regulation of HIV-1 latency by cytosine methylation","volume":"5","author":"Kauder","year":"2009","journal-title":"PloS Pathog"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2015.1063770","article-title":"Long non-coding RNA and chromatin remodeling","volume":"12","author":"Han","year":"2015","journal-title":"RNA Biol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605298103","article-title":"NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses","volume":"103","author":"Taganov","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B81","doi-asserted-by":"publisher","first-page":"18829","DOI":"10.1038\/s41598-019-55100-2","article-title":"Elevated expression of miR-146a correlates with high levels of immune cell exhaustion markers and suppresses cellular immune function in chronic HIV-1-infected patients","volume":"9","author":"Yu","year":"2019","journal-title":"Sci Rep"},{"key":"B82","doi-asserted-by":"crossref","first-page":"e1005254","DOI":"10.1371\/journal.ppat.1005254","article-title":"Interferon-alpha subtypes in an ex vivo model of acute HIV-1 infection: expression, potency and effector mechanisms","volume":"11","author":"Harper","year":"2015","journal-title":"PloS Pathog"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e0231120","DOI":"10.1128\/JVI.02311-20","article-title":"Differential inhibition of HIV replication by the 12 interferon alpha subtypes","volume":"95","author":"Tauzin","year":"2021","journal-title":"J Virol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.936918","article-title":"Distinct type I interferon subtypes differentially stimulate T cell responses in HIV-1-infected individuals","volume":"13","author":"Karakoese","year":"2022","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.6.1351","article-title":"Zidovudine and Interferon- Combination Therapy versus Zidovudine Mono therapy in Subjects with Symptomatic Human Immunodeficiency Virus Type 1 Infection","volume":"169","author":"Frissen","year":"1994","journal-title":"J Infect Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107270-00014","article-title":"Early control of HIV replication in primary HIV-1 infection treated wi th antiretroviral drugs and pegylated IFN\u03b1: results from the Primofero n A (ANRS 086) Study","volume":"15","author":"Emilie","year":"2001","journal-title":"AIDS"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1007675","article-title":"Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection","volume":"83","author":"Adalid-Peralta","year":"2008","journal-title":"J Leukoc Biol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328340a1e7","article-title":"Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial","volume":"25","author":"Boue","year":"2011","journal-title":"AIDS"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis663","article-title":"Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration","volume":"207","author":"Azzoni","year":"2013","journal-title":"J Infect Dis"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e1005000","DOI":"10.1371\/journal.ppat.1005000","article-title":"HIV reactivation from latency after treatment interruption occurs on average every 5\u20138 days\u2013implications for HIV remission","volume":"11","author":"Pinkevych","year":"2015","journal-title":"PloS Pathog"},{"key":"B91","article-title":"The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption","volume":"30","author":"Li","year":"2016","journal-title":"AIDS"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302536","article-title":"IFN-alpha exerts opposing effects on activation-induced and IL-7-induced proliferation of T cells that may impair homeostatic maintenance of CD4+ T cell numbers in treated HIV infection","volume":"193","author":"Cha","year":"2014","journal-title":"J Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4A0714-345RR","article-title":"Interferon-alpha inhibits CD4 T cell responses to interleukin-7 and interleukin-2 and selectively interferes with Akt signaling","volume":"97","author":"Nguyen","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37061","article-title":"Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B","volume":"123","author":"Di Martino","year":"2002","journal-title":"Gastroenterology"},{"key":"B95","article-title":"Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi\u2019s sarcoma","volume":"2","author":"Lane","year":"1988","journal-title":"Lancet"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00259-4","article-title":"Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients","volume":"16","author":"Prestileo","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"B97","doi-asserted-by":"publisher","first-page":"102945","DOI":"10.1016\/j.ebiom.2020.102945","article-title":"Interferon-alpha alters host glycosylation machinery during treated HIV infection","volume":"59","author":"Giron","year":"2020","journal-title":"EBioMedicine"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832f30ca","article-title":"Virologic and immunologic activity of PegIntron in HIV disease","volume":"23","author":"Angel","year":"2009","journal-title":"AIDS"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.5.1107","article-title":"Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity","volume":"173","author":"Skillman","year":"1996","journal-title":"J Infect Dis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-11-805","article-title":"Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial","volume":"112","author":"Lane","year":"1990","journal-title":"Ann Intern Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"110880","DOI":"10.1016\/j.celrep.2022.110880","article-title":"LL-37 transports\u00a0immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity","volume":"39","author":"Wei","year":"2022","journal-title":"Cell Rep"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00548","article-title":"Type I interferon regulates the expression of long non-coding RNAs","volume":"5","author":"Carnero","year":"2014","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84424","article-title":"Targeting noncoding RNAs in disease","volume":"127","author":"Adams","year":"2017","journal-title":"J Clin Invest"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00181","article-title":"Regulation of the interferon response by lncRNAs in HCV infection","volume":"9","author":"Valadkhan","year":"2018","journal-title":"Front Microbiol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2020.07.005","article-title":"Targeting long non-coding RNA to therapeutically regulate gene expression in cancer","volume":"21","author":"Fu","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1534","article-title":"Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults living with human immunodeficiency virus-1","volume":"72","author":"Riddler","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B107","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1038\/s41586-018-0721-y","article-title":"Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"564","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nature20583","article-title":"Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys","volume":"540","author":"Borducchi","year":"2016","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1736658\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:43:08Z","timestamp":1766040188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1736658\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":108,"alternative-id":["10.3389\/fimmu.2025.1736658"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1736658","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"1736658"}}